Show simple item record

dc.contributor.authorSánchez de la Torre, Alicia
dc.contributor.authorSoler, Xavier
dc.contributor.authorBarbé Illa, Ferran
dc.contributor.authorFlorés, Marina
dc.contributor.authorMaisel, Alan
dc.contributor.authorMalhotra, Atul
dc.contributor.authorRué i Monné, Montserrat
dc.contributor.authorBertran, Sandra
dc.contributor.authorAldomá, Albina
dc.contributor.authorWorner, Fernando
dc.contributor.authorValls Marsal, Joan
dc.contributor.authorLee, Chi-Hang
dc.contributor.authorTurino, Cecilia
dc.contributor.authorGalera, Estefanía
dc.contributor.authorBatlle Garcia, Jordi de
dc.contributor.authorSánchez de la Torre, Manuel
dc.description.abstractBackground: An analysis of cardiac injury markers in patients with OSA who sustain an episode of acute coronary syndrome (ACS) may contribute to a better understanding of the interactions and impact of OSA in subjects with ACS. We compared peak cardiac troponin I (cTnI) levels in patients with OSA and patients without OSA who were admitted for ACS. Methods: Blood samples were collected every 6 hours from the time of admission until two consecutive assays showed a downward trend in the cTnI assay. The highest value obtained defined the peak cTnI value, which provides an estimate of infarct size. Results: We included 89 patients with OSA and 38 patients without OSA with an apnea-hypopnea index of a median of 32 (interquartile range [IQR], 20.8-46.6/h and 4.8 [IQR, 1.6-9.6]/h, respectively. The peak cTnI value was significantly higher in patients without OSA than in patients with OSA (median, 10.7 ng/mL [IQR, 1.78-40.1 ng/mL] vs 3.79 ng/mL [IQR, 0.37-24.3 ng/mL]; P = .04). The multivariable linear regression analysis of the relationship between peak cTnI value and patient group, age, sex, and type of ACS showed that the presence or absence of OSA significantly contributed to the peak cTnI level, which was 54% lower in patients with OSA than in those without OSA. Conclusions: The results of this study suggest that OSA has a protective effect in the context of myocardial infarction and that patients with OSA may experience less severe myocardial injury. The possible role of OSA in cardioprotection should be explored in future studies.ca_ES
dc.description.sponsorshipFUNDING/SUPPORT: This work was supported by ResMed Ltd. (Australia), Fondo de Investigación Sanitaria (Fondo Europeo de Desarrollo Regional (FEDER) [PI10/02763 and PI10/02745]), the Spanish Respiratory Society (SEPAR), the Catalonian Cardiology Society, Esteve-Teijin (Spain), Oxigen Salud (Spain), and ALLER.
dc.relation.isformatofVersió postprint del document publicat a
dc.relation.ispartofChest, 2018, vol. 153, núm. 2, p. 329-338ca_ES
dc.rightscc-by-nc-nd (c) Elsevier, 2017ca_ES
dc.rights(c) American College of Chest Physicians. Published by Elsevier Inc., 2017
dc.subjectCardiac biomarkersca_ES
dc.subjectCardiovascular diseaseca_ES
dc.titleCardiac troponin values in patients with acute coronary syndrome and sleep apnea: a pilot studyca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by-nc-nd (c) Elsevier, 2017
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) Elsevier, 2017